Vaccine Program

Hepatitis B 

Viravaxx’ lead product is VVX001, a clinical Ph 2-stage Hepatitis B vaccine candidate. VVX001 is a recombinant fusion protein composed of PreS from the large surface antigen of HBV and synthetic peptides. Interim results from the ongoing trial with regard to the vaccine’s potential to induce Hepatitis B Virus neutralizing antibodies are currently being evaluated. For more information concerning the trial design and background publications go to ClinicalTrials.gov (NCT03625934).

 

Viravaxx HBV VVX001

VVX001 triggers an immune response which blocks the virus from binding to NTCP. This blocking activity inhibits virus entry.

VVX001 is currently in a clinical Ph 2 trial conducted in low-/non-responders as well as in chronically infected Hepatitis B patients.

 

Respiratory Syncytial Virus

As a result of research funded by Viravaxx and the Austrian Science Fund (FWF), the Valenta Labs currently investigate several RSV candidate vaccine constructs in immunological testing experiments. Contact Viravaxx for business development inquiries at info@viravaxx.com.

Background publications:

  • Borochova K, Niespodziana K, Focke-Tejkl M, Hofer G, Keller W, Valenta R. Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM responseScientific Reports (2021). Vol 11, 3551; https://www.nature.com/articles/s41598-021-82893-y.

     

  • Borochova K, Niespodziana K, Stenberg Hammar K, van Hage M, Hedlin G, Söderhäll C, Focke-Tejkl M, Valenta R. Features of the Human Antibody Response against Respiratory Syncytial Virus Surface Glycoprotein G. Vaccines (2020). 8(2):337; https://doi.org/10.3390/vaccines8020337.

Human Rhinovirus

As a result of research funded by Viravaxx, the Valenta Labs recently succeeded in defining binding sites for human rhinovirus by use of neutralizing antisera. Viravaxx is open to discuss its intellectual property base with interested companies. Contact Viravaxx for business development inquiries at info@viravaxx.com

Background publications:

  • Pazderova P, Waltl EE, Niederberger-Leppin V, Flicker S, Valenta R, Niespodziana K. ELISA-Based Assay for Studying Major and Minor Group Rhinovirus-Receptor Interactions. Vaccines (2020). 8(2): 315; https://doi.org/10.3390/vaccines8020315.

     

  • Sam Narean J, Glanville N, Nunn CM, Niespodziana K, Valenta R, Johnston SL, McLean GR. Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity. Vaccine (2019). 37(21): 2805-2813; https://doi.org/10.1016/j.vaccine.2019.04.018.

SARS-CoV-2 

Viravaxx’ SARS-CoV-2 blocking Antibody Test informs if a COVID-19 convalescent patient or vaccinated person has developed neutralizing antibodies which block the interaction of RBD with ACE2. We used our proprietary assay to analyze serum samples from patients who recovered from COVID-19. The findings helped us to understand the requirements for a vaccine to induce “sterilizing immunity”. This is of utmost importance since a significant percentage of COVID-19 convalescent patients do not produce antibodies capable of completely blocking RBD binding to the receptor protein ACE2. Our pre-clinical data suggest that Viravaxx’ vaccine candidate is able to induce sterilizing immunity also in those patients who develop RBD-ACE2 blocking antibodies with only suboptimal capacity. 
 
Background publications:
  • Gattinger P, Borochova K, Dorofeeva Y, Henning R, Kiss R, Kratzer B, Mühl B, Perkmann T, Trapin D, Trella M, Ettel P, Tulaeva I, Pickl W, Valenta R. Antibodies in serum of convalescent patients following mild COVID‐19 do not always prevent virus‐receptor binding. Allergy (2020). 00:1-6; https://doi.org/10.1111/all.14523.